FIGURE 3.

PDOs in HA‐Coll sponges can predict drug response of metastatic colorectal patients to FO therapy. (A) Waterfall plot of 12 patients’ overall responses and best responses of the biopsied lesion in the FO‐treated PDOs cohort. Red indicates PD, green indicates SD, and blue indicates PR (PR, partial response; SD, stable disease; PD, progressive disease). (B) Fitted dose‐response curves (DRCs) of 12 PDOs^Sponge exposed to FO in vitro. Red lines represent PDOs from PD patients(n = 6), green lines represent PDOs derived from SD patients (n = 2), and blue lines represent PDOs derived from PR patients (n = 4). IC50 represent in vitro sensitivity of PDOs to FO. (C and D) The IC50 values were quantified and the area under the DRC (AUC_DRC) was calculated by integrating the DRC of each PDO in (B). (E–G) Drug sensitivity of PDOs in Matrigel does not predict clinical response of parental colorectal patients to FO therapy. (E) Fitted dose–response curves (DRCs) of 12 PDOs^Matrigel exposed to FO in vitro. (F and G) The IC50 values were quantified and the area under the DRC (AUC_DRC) was calculated by integrating the DRC of each PDO in (E)